Arthritis News and Research

Latest Arthritis News and Research

Exactech receives FDA marketing clearance for Equinoxe Platform Fracture Stem

Exactech, Inc., a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that the company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the company’s Equinoxe® Platform Fracture Stem, the latest addition to the company’s shoulder arthroplasty line.

3 Mar 2010

OrthoDynamix' ArthroSteer 3.5mm Ablator for general surgical use receives FDA clearance

OrthoDynamix announced today that it has received FDA clearance for its new device, ArthroSteer 3.5mm Ablator, a mono polar electrosurgical device, for general surgical use, including the orthopedic and arthroscopic applications for resection, ablation, excision of soft tissue, hemostasis of blood vessels, and coagulating soft tissue in, but not limited to the knee, shoulder, and primarily the hip.

3 Mar 2010

Rigel Pharmaceuticals reports net loss of $0.48 per share for fourth-quarter 2009

Rigel Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009.

2 Mar 2010

GTC Biotherapeutics achieves high-level production of TG20 monoclonal antibody

GTC Biotherapeutics, Inc. announced that it has achieved high-level production of TG20; an anti-CD20 monoclonal antibody (MAb). The TG20 MAb, which is produced in the milk of transgenic goats, is being co-developed by GTC and LFB as part of the LFB-GTC joint venture.

2 Mar 2010

FDA works closely with different states to investigate the outbreak of Salmonella Montevideo infections

The Food and Drug Administration, along with the Centers for Disease Control and Prevention and the U.S. Department of Agriculture's Food Safety and Inspection Service, continues to work closely with the Rhode Island Department of Health and other states in the investigation of an outbreak of Salmonella Montevideo infections associated with certain Italian-style sausage products including salami/salame.

1 Mar 2010

Precise immune disturbances leading to Coeliac disease: More insight

New research has identified four aspects of immune system disturbance which lead to the development of coeliac disease. Nearly 40 different inherited risk factors which predispose to the disease have now been identified. These latest findings could speed the way towards improved diagnostics and treatments for the autoimmune complaint that affects 1 in 100 of the population, and lead to insights into related conditions such as type 1 diabetes.

28 Feb 2010

CPF to partner with ATS to fund Pulmonary Fibrosis research

The Coalition for Pulmonary Fibrosis and the American Thoracic Society, the world's leading professional organization for pulmonary, critical care and sleep physicians, today announced that the CPF will again partner with the ATS to fund Pulmonary Fibrosis (PF) research.

26 Feb 2010

Study demonstrates Prochymal treamtent is safe for cardiac patients

“Patients receiving Prochymal did better than those receiving only standard-of-care,” said Dr. Hare, lead author of the JACC publication.

25 Feb 2010

Increase in anti-Apo A-I, anti-HDL and anti-CRP may lead to atherosclerosis in SLE patients

A study by researchers in Australia and the United Kingdom suggests that autoantibodies to fat binding proteins significantly increase in systemic lupus erythematosus (SLE) patients with active disease. This increase in anti-apolipoprotein (anti-Apo A-I), anti-high-density lipoprotein (anti-HDL), and anti-C-reactive protein (anti-CRP) may contribute to the development of atherosclerosis in SLE patients, placing them at risk for cardiovascular disease (CVD).

25 Feb 2010

Prevalence of arthritis and AAL may be effect of obesity and physical inactivity, particularly in women

Researchers from the Toronto Western Research Institute noted a higher prevalence of arthritis and arthritis-attributable activity limitations (AAL) in the U.S. versus the Canadian population. The authors attribute the higher prevalence of arthritis and AAL to a greater level of obesity and physical inactivity in Americans, particularly women.

25 Feb 2010

End-stage ankle arthritis: New treatment options for baby boomers

There's good news for active older adults who are plagued with arthritic ankles. Surgeons presenting today at the American College of Foot and Ankle Surgeons' Annual Scientific Conference in Las Vegas are re-thinking treatment approaches for end-stage ankle arthritis.

25 Feb 2010

SSRIs exhibit anti-inflammatory effects and may provide drug development opportunities for RA

A new study found that fluoxetine (Prozac-) and citalopram (Celexa-) treatment significantly inhibited disease progression of collagen-induced arthritis (CIA) in mice. Research led by Sandra Sacre, Ph.D. from the Brighton and Sussex Medical School (BSMS) in the UK studied the anti-arthritic potential of these drugs, known as selective serotonin reuptake inhibitors (SSRIs), most commonly used to treat depression.

25 Feb 2010

Osiris Therapeutics' net income for fourth-quarter 2009 increases to $15.7M

Osiris Therapeutics, Inc., the leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular and orthopedic areas, announced today its results for the fourth quarter and year ended December 31, 2009.

24 Feb 2010

Over-produced PKC-iota oncogene linked to poor pancreatic cancer patient survival

Researchers at the Mayo Clinic campus in Florida have found that PKC-iota (PKC), an oncogene important in colon and lung cancers, is over-produced in pancreatic cancer and is linked to poor patient survival. They also found that genetically inhibiting PKC in laboratory animals led to a significant decrease in pancreatic tumor growth and spread.

24 Feb 2010

Prochymal achieves response rate of 63% when used as rescue therapy in children suffering from GvHD

Osiris Therapeutics, Inc. today reported that a new study shows Prochymal achieved an overall response rate of 63% when used as a rescue therapy in children suffering from severe treatment resistant graft vs. host disease (GvHD).

24 Feb 2010

Phase III trial results of Osiris Therapeutics' Prochymal for GvHD to be presented at BMT Tandem Meeting

Osiris Therapeutics, Inc. today announced that results from the Phase III trial evaluating Prochymal for the treatment of steroid-refractory acute graft vs. host disease (GvHD) will be presented by Paul Martin, M.D., of the Fred Hutchinson Cancer Research Center and Paul Szabolcs, M.D., of Duke University Medical Center at the 2010 BMT Tandem Meeting. The meeting is being held February 24-28 in Orlando, Florida.

24 Feb 2010

Idera Pharmaceuticals presents IMO-3100 TLR antagonist mechanism of action data at Keystone conference

Idera Pharmaceuticals, Inc. today presented data on the mechanism of action of IMO-3100, an antagonist of Toll-like Receptor (TLR) 7 and TLR9, in a preclinical primate model at the Keystone Symposia conference “Tolerance and Autoimmunity” being held February 21-26 in Taos, New Mexico. Idera is developing IMO-3100 for the treatment of autoimmune diseases. The presentation entitled “IMO-3100, a novel antagonist, suppresses TLR7- and TLR9-mediated immune responses in non-human primates” was made by Idera scientists.

24 Feb 2010

Religious belief can reduce depression symptoms

Research suggests that religious belief can help protect against symptoms of depression, but a study at Rush University Medical Center goes one step further.

24 Feb 2010

Researchers receive grant to study how ILD appears in patients with autoimmune diseases

Researchers at the University of Cincinnati Interstitial Lung Disease Center have received a grant from the National Heart, Lung and Blood Institute to study ways ILD first appears in certain patient groups with autoimmune diseases and how to more efficiently diagnose and treat it.

24 Feb 2010

Rising Medicare costs linked to the growth in common costly chronic conditions: Study

Today, two of the nation's leading health and fiscal policy experts discussed how to reign in rising health care costs in Medicare in light of a new Health Affairs study that shows rising Medicare costs in the nation's health care system are linked to the growth in several common costly chronic conditions, such as diabetes, arthritis, hypertension, and kidney disease.

24 Feb 2010

Arthritis News and Research

Latest Arthritis News and Research

Exactech receives FDA marketing clearance for Equinoxe Platform Fracture Stem

OrthoDynamix' ArthroSteer 3.5mm Ablator for general surgical use receives FDA clearance

Rigel Pharmaceuticals reports net loss of $0.48 per share for fourth-quarter 2009

GTC Biotherapeutics achieves high-level production of TG20 monoclonal antibody

FDA works closely with different states to investigate the outbreak of Salmonella Montevideo infections

Precise immune disturbances leading to Coeliac disease: More insight

CPF to partner with ATS to fund Pulmonary Fibrosis research

Study demonstrates Prochymal treamtent is safe for cardiac patients

Increase in anti-Apo A-I, anti-HDL and anti-CRP may lead to atherosclerosis in SLE patients

Prevalence of arthritis and AAL may be effect of obesity and physical inactivity, particularly in women

End-stage ankle arthritis: New treatment options for baby boomers

SSRIs exhibit anti-inflammatory effects and may provide drug development opportunities for RA

Osiris Therapeutics' net income for fourth-quarter 2009 increases to $15.7M

Over-produced PKC-iota oncogene linked to poor pancreatic cancer patient survival

Prochymal achieves response rate of 63% when used as rescue therapy in children suffering from GvHD

Phase III trial results of Osiris Therapeutics' Prochymal for GvHD to be presented at BMT Tandem Meeting

Idera Pharmaceuticals presents IMO-3100 TLR antagonist mechanism of action data at Keystone conference

Religious belief can reduce depression symptoms

Researchers receive grant to study how ILD appears in patients with autoimmune diseases

Rising Medicare costs linked to the growth in common costly chronic conditions: Study

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Arthritis News and Research

Latest Arthritis News and Research

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Newsletters you may be interested in